GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXX) » Definitions » Cash Flow from Investing

Lexaria Bioscience (Lexaria Bioscience) Cash Flow from Investing : $-0.20 Mil (TTM As of Feb. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Lexaria Bioscience Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Feb. 2024, Lexaria Bioscience spent $0.06 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.06Mil for net Intangibles purchase and sale. And it received $0.06 Mil from other investing activities. In all, Lexaria Bioscience spent $0.06 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Feb. 2024.


Lexaria Bioscience Cash Flow from Investing Historical Data

The historical data trend for Lexaria Bioscience's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience Cash Flow from Investing Chart

Lexaria Bioscience Annual Data
Trend Oct13 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.77 -0.03 0.19 -0.18 -0.17

Lexaria Bioscience Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.03 -0.07 -0.04 -0.06

Lexaria Bioscience Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Lexaria Bioscience's Cash Flow from Investing for the fiscal year that ended in Aug. 2023 is calculated as:

Lexaria Bioscience's Cash Flow from Investing for the quarter that ended in Feb. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lexaria Bioscience  (NAS:LEXX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Lexaria Bioscience's purchase of property, plant, equipment for the three months ended in Feb. 2024 was $-0.06 Mil. It means Lexaria Bioscience spent $0.06 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Lexaria Bioscience's sale of property, plant, equipment for the three months ended in Feb. 2024 was $0.00 Mil. It means Lexaria Bioscience gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Lexaria Bioscience's purchase of business for the three months ended in Feb. 2024 was $0.00 Mil. It means Lexaria Bioscience spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Lexaria Bioscience's sale of business for the three months ended in Feb. 2024 was $0.00 Mil. It means Lexaria Bioscience gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Lexaria Bioscience's purchase of investment for the three months ended in Feb. 2024 was $0.00 Mil. It means Lexaria Bioscience spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Lexaria Bioscience's sale of investment for the three months ended in Feb. 2024 was $0.00 Mil. It means Lexaria Bioscience gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Lexaria Bioscience's net Intangibles purchase and sale for the three months ended in Feb. 2024 was $-0.06 Mil. It means Lexaria Bioscience paid $0.06 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Lexaria Bioscience's cash from discontinued investing activities for the three months ended in Feb. 2024 was 0.00 Mil. It means Lexaria Bioscience paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Lexaria Bioscience's cash from other investing activities for the three months ended in Feb. 2024 was $0.06 Mil. It means Lexaria Bioscience received $0.06 Mil from other investing activities.


Lexaria Bioscience Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexaria Bioscience (Lexaria Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
Executives
Catherine C. Turkel director 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Gregory Downey officer: Chief Financial Officer 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Christopher Bunka director, 10 percent owner, officer: CEO 1924 BIRKDALE AVE, KELOWNA A1 V1P1R7
Vanessa Carle officer: Secretary 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Reese Albert L Jr director
Brian W. Quigley director 100 740 MCCURDY ROAD, KELOWNA A1 23230
William Edward Mckechnie director 305 MARGARET AVENUE, KITCHENER A6 N2H 6S4
Allan Horst Spissinger officer: CFO 8131 198A STREET, LANGLEY A1 V2Y 1Y6
John Martin Docherty director, 10 percent owner 23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1
Baljinder Bhullar director, officer: CFO 604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8
Nicholas W Baxter director 220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Dustin Arthur Elford director 888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4
Thomas James Ihrke officer: Sr. VP, Business Development 38 KRIER LANE, MOUNT PLEASANT SC 29464
David Demartini director, 10 percent owner 11714 SPRIGGS WAY, HOUSTON TX 77024
Leonard Macmillan director, officer: Vice President - Corp Develop SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6